Literature DB >> 29954937

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load.

Sebastian Vosberg1,2,3,4, Luise Hartmann1,2,3,4, Klaus H Metzeler1,2,3,4, Nikola P Konstandin4, Stephanie Schneider4,5, Ashok Varadharajan6, Andreas Hauser6, Stefan Krebs6, Helmut Blum6, Stefan K Bohlander7, Wolfgang Hiddemann1,2,3,4, Johanna Tischer8, Karsten Spiekermann1,2,3,4, Philipp A Greif9,2,3,4.   

Abstract

Entities:  

Year:  2018        PMID： 29954937      PMCID： PMC6269290          DOI： 10.3324/haematol.2018.193102

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation.

Authors:  Michael A Nalesnik; George Tseng; Ying Ding; Guo-Sheng Xiang; Zhong-liang Zheng; YanPing Yu; James W Marsh; George K Michalopoulos; Jian-Hua Luo
Journal:  Am J Pathol       Date:  2012-02-08       Impact factor: 4.307

2.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

3.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Authors:  Hsin-An Hou; Tai-Chung Huang; Liang-In Lin; Chieh-Yu Liu; Chien-Yuan Chen; Wen-Chien Chou; Jih-Luh Tang; Mei-Hsuan Tseng; Chi-Fei Huang; Ying-Chieh Chiang; Fen-Yu Lee; Ming-Chih Liu; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

4.  Frontrunners of T cell activation: Initial, localized Ca2+ signals mediated by NAADP and the type 1 ryanodine receptor.

Authors:  Insa M A Wolf; Björn-Philipp Diercks; Ellen Gattkowski; Frederik Czarniak; Jan Kempski; René Werner; Daniel Schetelig; Hans-Willi Mittrücker; Valéa Schumacher; Manuel von Osten; Dimitri Lodygin; Alexander Flügel; Ralf Fliegert; Andreas H Guse
Journal:  Sci Signal       Date:  2015-10-13       Impact factor: 8.192

5.  Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Authors:  Tobias Herold; Klaus H Metzeler; Sebastian Vosberg; Luise Hartmann; Christoph Röllig; Friedrich Stölzel; Stephanie Schneider; Max Hubmann; Evelyn Zellmeier; Bianka Ksienzyk; Vindi Jurinovic; Zlatana Pasalic; Purvi M Kakadia; Annika Dufour; Alexander Graf; Stefan Krebs; Helmut Blum; Maria Cristina Sauerland; Thomas Büchner; Wolfgang E Berdel; Bernhard J Woermann; Martin Bornhäuser; Gerhard Ehninger; Ulrich Mansmann; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann; Philipp A Greif
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

6.  High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.

Authors:  Anna Candoni; Federico De Marchi; Maria Elena Zannier; Davide Lazzarotto; Carla Filì; Maria Vittoria Dubbini; Nicholas Rabassi; Eleonora Toffoletti; Bonnie W Lau; Renato Fanin
Journal:  Leuk Res       Date:  2017-10-27       Impact factor: 3.156

Review 7.  Relapse after allogeneic stem cell transplantation.

Authors:  A John Barrett; Minoo Battiwalla
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

8.  Gain of function in the immune system caused by a ryanodine receptor 1 mutation.

Authors:  Mirko Vukcevic; Francesco Zorzato; Simone Keck; Dimitrios A Tsakiris; Jennifer Keiser; Rick M Maizels; Susan Treves
Journal:  J Cell Sci       Date:  2013-05-23       Impact factor: 5.285

9.  Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Authors:  Philipp A Greif; Luise Hartmann; Sebastian Vosberg; Sophie M Stief; Raphael Mattes; Ines Hellmann; Klaus H Metzeler; Tobias Herold; Stefanos A Bamopoulos; Paul Kerbs; Vindi Jurinovic; Daniela Schumacher; Friederike Pastore; Kathrin Bräundl; Evelyn Zellmeier; Bianka Ksienzyk; Nikola P Konstandin; Stephanie Schneider; Alexander Graf; Stefan Krebs; Helmut Blum; Martin Neumann; Claudia D Baldus; Stefan K Bohlander; Stephan Wolf; Dennis Görlich; Wolfgang E Berdel; Bernhard J Wörmann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Clin Cancer Res       Date:  2018-01-12       Impact factor: 12.531

10.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Authors:  Klaus H Metzeler; Tobias Herold; Maja Rothenberg-Thurley; Susanne Amler; Maria C Sauerland; Dennis Görlich; Stephanie Schneider; Nikola P Konstandin; Annika Dufour; Kathrin Bräundl; Bianka Ksienzyk; Evelyn Zellmeier; Luise Hartmann; Philipp A Greif; Michael Fiegl; Marion Subklewe; Stefan K Bohlander; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Jan Braess; Karsten Spiekermann
Journal:  Blood       Date:  2016-06-10       Impact factor: 22.113
View more
  6 in total

1.  Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.

Authors:  Raksha Shrestha; Mamiko Sakata-Yanagimoto; Koichiro Maie; Motohiko Oshima; Masatomo Ishihara; Yasuhito Suehara; Kota Fukumoto; Yaeko Nakajima-Takagi; Hirotaka Matsui; Takayasu Kato; Hideharu Muto; Tatsuhiro Sakamoto; Manabu Kusakabe; Yasuhito Nannya; Hideki Makishima; Hiroo Ueno; Ryunosuke Saiki; Seishi Ogawa; Kenichi Chiba; Yuichi Shiraishi; Satoru Miyano; Enguerran Mouly; Olivier A Bernard; Toshiya Inaba; Haruhiko Koseki; Atsushi Iwama; Shigeru Chiba
Journal:  Blood Adv       Date:  2020-03-10

2.  Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Authors:  Laura K Schmalbrock; Anna Dolnik; Sibylle Cocciardi; Eric Sträng; Frauke Theis; Nikolaus Jahn; Ekaterina Panina; Tamara J Blätte; Julia Herzig; Sabrina Skambraks; Frank G Rücker; Verena I Gaidzik; Peter Paschka; Walter Fiedler; Helmut R Salih; Gerald Wulf; Thomas Schroeder; Michael Lübbert; Richard F Schlenk; Felicitas Thol; Michael Heuser; Richard A Larson; Arnold Ganser; Hendrik G Stunnenberg; Saverio Minucci; Richard M Stone; Clara D Bloomfield; Hartmut Döhner; Konstanze Döhner; Lars Bullinger
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

Review 3.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 4.  Clonal evolution of acute myeloid leukemia from diagnosis to relapse.

Authors:  Sebastian Vosberg; Philipp A Greif
Journal:  Genes Chromosomes Cancer       Date:  2019-09-03       Impact factor: 5.006

5.  Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.

Authors:  Daelynn R Buelow; Stanley B Pounds; Yong-Dong Wang; Lei Shi; Yongjin Li; David Finkelstein; Sheila Shurtleff; Geoffrey Neale; Hiroto Inaba; Raul C Ribeiro; Reid Palumbo; Dominique Garrison; Shelley J Orwick; James S Blachly; Karl Kroll; John C Byrd; Tanja A Gruber; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  Clin Transl Sci       Date:  2019-08-20       Impact factor: 4.689

Review 6.  CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.